Search Results
Feb 19, 2026, 02:00 ET A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants
Very Low Birth Weight (VLBW) Infants") informed Japan's world-class Pharmaceuticals and Medical Devices Agency's (PMDA) review. The Japanese-led phase III, randomized, controlled, open-label, multicenter trial evaluated growth and safety associated with Prolacta's 100% human milk-based fortifiers, demonstrating significantly
More news about: Prolacta Bioscience
Feb 19, 2026, 00:00 ET A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants
Very Low Birth Weight (VLBW) Infants") informed Japan's world-class Pharmaceuticals and Medical Devices Agency's (PMDA) review. The Japanese-led phase III, randomized, controlled, open-label, multicenter trial evaluated growth and safety associated with Prolacta's 100% human milk-based fortifiers, demonstrating significantly
More news about: Prolacta Bioscience
Feb 18, 2026, 20:49 ET Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Ultragenyx's Phase III Orbit study would fail to achieve a statistically significant reduction in annualized fracture rate ("AFR"), such that the second interim analysis could be performed and presented to the investing public; (2) in truth, Ultragenyx's optimism in the Phase III Orbit study's results
More news about: Kessler Topaz Meltzer & Check, LLP
Feb 18, 2026, 17:31 ET Phenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates | DelveInsight
ODD and EMA PRIME eligibility, highlighting its potential to address significant unmet needs in PKU. The drug is currently being evaluated in a Phase III clinical trial in adult patients with phenylketonuria.The anticipated launch of these emerging therapies are poised to transform the phenylketonuria
More news about: DelveInsight Business Research, LLP
Feb 18, 2026, 16:43 ET ENPH Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Enphase Energy, Inc.
allowed homeowners to deduct 30% of costs of clean energy property they install at their homes) on December 31, 2025 instead of December 21, 2032; and (iii) accordingly, Enphase overstated its financial and operational prospects.Plaintiff alleges that on October 28, 2025, Enphase reported
More news about: Robbins LLP
Feb 18, 2026, 16:35 ET AMERICAN WATER REPORTS STRONG 2025 RESULTS; AFFIRMS 2026 EPS GUIDANCE AND LONG-TERM TARGETS
during 2026 related to the proposed merger with Essential Utilities, Inc. ("Essential Utilities"), (ii) impacts of weather, if any, during 2026, and (iii) incremental interest income through February 13, 2026 related to the 2024 amendment of the former Homeowner Services Group ("HOS") secured seller note.
More news about: American Water
Feb 18, 2026, 16:20 ET ONE Gas Announces Fourth Quarter and Full Year 2025 Financial Results; Releases Non-GAAP Adjusted Financial Guidance
prior to or when they become due and to fund our operations and capital expenditures, either through (i) cash on hand, (ii) operating cash flow, or (iii) access to the capital markets and other sources of liquidity;our ability to obtain capital on commercially reasonable terms, or on terms acceptable
More news about: ONE Gas, Inc.
Feb 18, 2026, 16:19 ET Blue Owl Capital Corporation Announces December 31, 2025 Financial Results
results and trends, as well as its performance, excluding non-cash income or gains related to the merger between the Company and Blue Owl Capital Corp. III ("OBDE") (such merger, the "OBDE Merger"), which closed on January 13, 2025. The presentation of non-GAAP measures is not intended to be a substitute
More news about: Blue Owl Capital Corporation
Feb 18, 2026, 16:15 ET Brookdale Announces Fourth Quarter and Full Year 2025 Results
as part of the Company's underlying core operating performance and that management believes impact the comparability of performance between periods; (iii) the Company believes that this measure is used by research analysts and investors to evaluate the Company's operating results and to value companies
More news about: Brookdale Senior Living Inc.
Feb 18, 2026, 16:05 ET Western Midstream Announces Record Fourth-Quarter and Full-Year 2025 Results
Partners, LP ("Adjusted EBITDA") as net income (loss), plus (i) distributions from equity investments, (ii) non-cash equity-based compensation expense, (iii) interest expense, (iv) income tax expense, (v) depreciation and amortization, (vi) impairments, and (vii) other expense (including lower of cost or
More news about: Western Midstream Partners, LP
Feb 18, 2026, 16:05 ET GRAND CANYON EDUCATION, INC. REPORTS FOURTH QUARTER 2025 RESULTS
the occurrence of any event, change or other circumstance that could give rise to the termination of any of the key university partner agreements; (iii) our ability to properly manage risks and challenges associated with strategic initiatives, including potential acquisitions or divestitures of, or investments
More news about: Grand Canyon Education, Inc.
Feb 18, 2026, 16:05 ET BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS
measure) adjusted for: (i) payments of legacy legal settlements, net of insurance recoveries and restitutions, (ii) payments of transformation costs, (iii) payments for separation costs and separation-related costs, (iv) interest payments charged against premium, (v) fees paid in connection with the debt
More news about: Bausch Health Companies Inc.
Feb 18, 2026, 13:07 ET Bitmine Immersion Technologies (BMNR) Umumkan Kepemilikan ETH Mencapai 4,371 Juta Token dan Total Kepemilikan Kripto Maupun Total Uang Tunai Sebesar $9,6 Miliar
Bitmine tetap didukung oleh kelompok penting beranggotakan investor institusi seperti Cathie Wood dari ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital, dan investor pribadi Thomas "Tom" Lee guna mendukung tujuan Bitmine untuk mengakuisisi 5% ETH
More news about: Bitmine Immersion Technologies, Inc.
Feb 18, 2026, 12:43 ET Shrub Oak International School Announces Promotion of Laura Meyers, LCAT, ATR-BC, to Director of The Pines at Shrub Oak
support.Shrub Oak International School is accredited by:The National Independent Private Schools Association (NIPSA), Level III Therapeutic Certification, Academic Accreditation, with an Autism Endorsement;The Middle States Association Commission on
More news about: Shrub Oak International School
Feb 18, 2026, 11:00 ET Automotive Refrigerator Market Set for Growth Driven by Rising Demand for In-Vehicle Comfort, Electrification Trends, and Expansion of Long-Distance Mobility - Market Research Intellect
Channel Opener Market By Product (Type I (Small‑Molecule Therapeutics), Type II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare
More news about: Market Research Intellect
Feb 18, 2026, 10:45 ET Cybersecurity Software Market Driven by Escalating Cyber Threats, Rapid Digital Transformation, and Expanding Enterprise Security Investments - Market Research Intellect
Channel Opener Market By Product (Type I (Small‑Molecule Therapeutics), Type II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare
More news about: Market Research Intellect
Feb 18, 2026, 10:00 ET Grant & Eisenhofer P.A. and Levi & Korsinsky, LLP Announces Summary Notice of Pendency and Proposed Settlement of Stockholder Class Action for All Record and Beneficial Holders of Experience Investment Corp. Class A Common Stock Who Purchased, Acquired, or Held Such Securities at Any Time Between September 17, 2019 and May 3, 2021
SUCCESSORS-IN-INTEREST WHO OBTAINED SHARES BY OPERATION OF LAW, BUT EXCLUDING: (I) DEFENDANTS; (II) MEMBERS OF THE IMMEDIATE FAMILY OF ANY INDIVIDUAL DEFENDANT; (III) ANY PARENT, SUBSIDIARY, OR AFFILIATE OF ANY ENTITY DEFENDANT; (IV) ANY ENTITY IN WHICH ANY DEFENDANT OR ANY OTHER EXCLUDED PERSON, OR GROUP OF EXCLUDED
More news about: Grant & Eisenhofer P.A. and Levi & Korsinsky, LLP
Feb 18, 2026, 09:05 ET 2026 Palisade Hybrid Wins Edmunds' Highest Honor: Edmunds Top Rated Best of the Best
estimates and for comparison purposes only. Actual mileage may vary with options, driving conditions, driving habits and vehicle's condition.iii Approximately 20 minutes to charge from 10% to 80% on a 350-kW, 800V DC ultra-fast charger using the CCS adapter included with the 2026 IONIQ 5.
More news about: Hyundai Motor America
Feb 18, 2026, 09:03 ET A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants
Very Low Birth Weight (VLBW) Infants") informed Japan's world-class Pharmaceuticals and Medical Devices Agency's (PMDA) review. The Japanese-led phase III, randomized, controlled, open-label, multicenter trial evaluated growth and safety associated with Prolacta's 100% human milk-based fortifiers, demonstrating significantly
More news about: Prolacta Bioscience
Feb 18, 2026, 09:00 ET Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 - RARE
decrease in annualized fracture rates or otherwise the Phase III Orbit and Cosmic studies were much less likely to be able to demonstrate such a link than management claimed. On December 29, 2025, Ultragenyx announced that both its Phase III Orbit and Cosmic Studies had not "achieved statistical significance
More news about: Levi & Korsinsky, LLP
Feb 18, 2026, 09:00 ET April 3, 2026 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against PLUG
facilities necessary to receive those funds; (ii) as such, Plug Power was likely to pivot toward more modest projects with less commercial upside; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.WHAT'S NEXT? If you suffered a
More news about: Levi & Korsinsky, LLP
Feb 18, 2026, 09:00 ET Beyond Meat, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BYND
material, non-cash impairment charge; (ii) the foregoing was likely to impair Beyond Meat's ability to timely file its periodic filings with the SEC; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times.WHAT'S NEXT? If you suffered a loss
More news about: Levi & Korsinsky, LLP
Feb 18, 2026, 09:00 ET March 13, 2026 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CRWV
that CoreWeave's reliance on a single third-party data center supplier presented for CoreWeave's ability to meet customer demand for its services; (iii) the foregoing was reasonably likely to have a material negative impact on the Company's revenue; (iv) as a result, the Company's public statements were
More news about: Levi & Korsinsky, LLP
Feb 18, 2026, 09:00 ET Class Action Filed Against Inovio Pharmaceuticals, Inc. (INO) - April 7, 2026 Deadline to Join - Contact Levi & Korsinsky
device was deficient; (ii) accordingly, Inovio was unlikely to submit it's lead product candidate, INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's
More news about: Levi & Korsinsky, LLP
Feb 18, 2026, 09:00 ET Elsevier expands ClinicalKey AI with unrivaled full-text knowledge base and technology upgrades to help clinicians make decisions with confidence
Medical Oncology, the American College of Emergency Physicians, the American Gastroenterological Association and many more.Joseph W. St. Geme III, MD, Physician-in-Chief at the Children's Hospital of Philadelphia, said: "I find ClinicalKey AI to be a very helpful source of information that facilitates
More news about: Elsevier Limited